ClinicalTrials.gg
CompletedNCT05462756QWINT-4Updated Apr 27, 2025Results posted

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

A Phase 3 interventional study of Insulin Efsitora Alfa and Insulin Lispro (U100) in Type 2 Diabetes and Type 2 Diabetes Treated With Insulin, sponsored by Eli Lilly and Company. Completed at 81 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
730
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing insulin efsitora alfa in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. insulin efsitora alfa · Diabetes Mellitus, Type 2.

Enrollment
4th of 14
730 · median 75
Started
2022
with 3 others
Phase 3
4 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
14 of 14
Eli Lilly and Company

Among the 14 studies testing insulin efsitora alfa in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 4 that started in 2022, is one of 4 in phase 3, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 14 studies testing insulin efsitora alfa in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About insulin efsitora alfa

insulin efsitora alfa: first FDA approval 2026 (ONSWIK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing insulin efsitora alfa in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandial insulin. The study consists of a 3-week screening/lead-in period, a 26-week treatment period and a 5-week safety follow-up period. The study will last up to 34 weeks.

03

Conditions studied

  • Type 2 Diabetes
  • Type 2 Diabetes Treated With Insulin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of T2D according to the world health organization (WHO) criteria, currently treated with basal insulin and at least 2 injections of prandial insulin per day.
  • Are receiving ≥10 units of total basal insulin per day at screening.
  • Are receiving ≤2 units/kilogram/day of total daily insulin at screening
  • Have an value of 7.0% to 10%, inclusive, as determined by the central laboratory at screening
  • Have been treated with a stable regimen of one of the following basal insulins used according to local product label with or without noninsulin diabetes therapy for at least 90 days prior to screening

    • once daily U-100 or U-200 insulin degludec
    • once daily U-100 or U-300 insulin glargine
    • once or twice daily U-100 insulin detemir or
    • once or twice daily human insulin Neutral Protamine Hagedorn
  • Have been treated with at least twice daily dosing of one of the following insulins used according to local product label for at least 90 days prior to screening. One dose of prandial insulin must occur at the evening meal.

    • Insulin lispro-aabc
    • Insulin lispro (U-100 and U-200)s, IN], U-100 or U200)
    • Insulin aspart (U-100)
    • Insulin glulisine (U-100), or
    • Regular insulin (U-100)
  • Acceptable noninsulin diabetes therapies may include 0 to up to 3 of the following with a stable dose for at least 90 days prior to screening

    • dipeptidyl peptidase IV inhibitors
    • sodium-glucose co-transporter-2 inhibitors
    • biguanides (for example, metformin), or
    • glucagon-like peptide-1 receptor agonists Note: All noninsulin diabetes therapies must be used in accordance with the corresponding local product label at the time of screening, and participants should be willing to continue stable dosing throughout the study
    • Have a ≤45 kilogram/square meter (kg/m²)

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of type 1 diabetes mellitus or latent diabetes, or specific type of diabetes other than T2D (for example, monogenic diabetes, diseases of the exocrine pancreas, drug-induced or chemical-induced diabetes).
  • Are currently receiving any of the following insulin therapies anytime in the past 90 days:

    • insulin mixtures
    • insulin human, inhalation powder, or
    • continuous subcutaneous insulin infusion therapy, or
    • regular insulin U-500
  • Have a history of greater than 1 episode of ketoacidosis or hyperosmolar state/coma requiring hospitalization in the 6 months prior to screening
  • Have had any episodes of severe hypoglycemia, defined as requiring assistance due to neurologically disabling hypoglycemia, within the 6 months prior to screening
  • Have hypoglycemia unawareness in the opinion of the investigator
  • Anticipate making changes in personal CGM or flash glucose monitoring (FGM) use (for example, initiation, stopping, or changing device) during the study.
  • Have had Class IV heart failure or any of the following cardiovascular conditions in the past 3 months prior to screening: acute myocardial infarction, cerebrovascular accident (stroke), or coronary bypass surgery.
  • Have undergone gastric bypass (bariatric) surgery, restrictive bariatric surgery, or sleeve gastrectomy within 1 year prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
730 participants (actual)

Study arms

  • Experimental
    500 U/mL - Insulin Efsitora

    Participants received 500 units per milliliter (U/mL) Insulin Efsitora Alfa (insulin efsitora) administered subcutaneously (SC) once weekly (QW) along with 100 U/mL insulin lispro given SC with meals as needed.

    Drug: Insulin Efsitora Alfa · Drug: Insulin Lispro (U100)

  • Active comparator
    100 U/mL - Insulin Glargine

    Participants received 100 U/mL insulin glargine administered SC once daily (QD) along with 100 U/mL insulin lispro given SC with meals as needed.

    Drug: Insulin Lispro (U100) · Drug: Insulin Glargine (U100)

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority]

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Baseline, Week 26

Secondary outcomes

  1. Change From Baseline in HbA1c [Superiority]

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

    Time frame: Baseline, Week 26

  2. Percentage of Participants Achieving HbA1c <7% Without Nocturnal Hypoglycemia

    Percentage of participants achieving HbA1c \<7% without nocturnal hypoglycemia \[\<54 milligram/deciliter (mg/dL) 3.0 millimole/Liter (mmol/L)\] or severe during treatment phase up to week 26. Nocturnal hypoglycemia is a hypoglycemia event, including severe hypoglycemia, that occurs at night and presumably during sleep between midnight and 6:00 am.

    Time frame: Week 26

  3. Nocturnal Hypoglycemia Event Rate

    The event rate of participant-reported clinically significant nocturnal hypoglycemia, (where glucose \<54 mg/dL (3.0 mmol/L) or severe and occurs at night and presumably during sleep between midnight and 6:00 AM), measured during treatment phase up to week 26. Group mean is reported here.

    Time frame: Baseline Up To Week 26

  4. Change From Baseline in Fasting Glucose

    Change from baseline in fasting glucose measured by self-monitoring blood glucose (SMBG).

    Time frame: Baseline, Week 26

  5. Percentage of Time in Glucose Range

    Percentage of Time in glucose range between 70 and 180 mg/dL (3.9 and 10.0 mmol/L), inclusive measured during the continuous glucose monitoring (CGM) session.

    Time frame: Week 22 to Week 26

  6. Percentage of Time in Hypoglycemia Range

    Percentage of Time in hypoglycemia range with glucose \<54 mg/dL (3.0 mmol/L), measured by CGM.

    Time frame: Week 22 to Week 26

  7. Percentage of Time in Hyperglycemia Range

    Percentage of Time in hyperglycemia range with glucose \>180 mg/dL (10.0 mmol/L), measured by CGM.

    Time frame: Week 22 to Week 26

  8. Glucose Variability Between Weeks 22 to 26

    Glucose variability measured as coefficient of variation for glucose within day for 24-hour period between Week 22 and 26 was reported.

    Time frame: Week 22 to Week 26

  9. Basal Insulin Dose at Week 26

    Average weekly basal Insulin Dose at Week 26 was reported.

    Time frame: Week 26

  10. Bolus Insulin Dose at Week 26

    Average daily bolus Insulin Dose at Week 26 was reported.

    Time frame: Week 26

  11. Total Insulin Dose at Week 26

    Average total weekly insulin dose at Week 26 was reported.

    Time frame: Week 26

  12. Basal Insulin Dose to Total Insulin Dose Ratio at Week 26

    Basal insulin dose to total insulin dose ratio at Week 26 was reported.

    Time frame: Week 26

  13. Hypoglycemia Event Rate

    Hypoglycemia event rate was reported. Hypoglycemia with glucose \<54 mg/dL (Level 2) or Severe Hypoglycemia (Level 3) was reported. A severe hypoglycemic event is characterized by altered mental or physical status requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions for the treatment of hypoglycemia. Group mean was reported here.

    Time frame: Baseline up to Week 26

  14. Change From Baseline in Body Weight

    Change from baseline in body weight was reported.

    Time frame: Baseline, Week 26

  15. Treatment Experience for Diabetes Injection Device at Week 26 - Experience Questionnaire (DID-EQ)

    The DID-EQ is a self-administered, 10-item questionnaire designed to assess participants' perceptions of diabetes injection delivery systems for diabetes. The Device Characteristic Subscale is comprised of items 1 to 7 which focus on specific characteristics of injection devices. Each item is rated on a four-point Likert scale. Scores are transformed and range from 0 to 100. Higher scores indicate more positive perceptions of injection device characteristics

    Time frame: Week 26

07

Results

Posted Apr 27, 2025

Participant flow

Participants underwent a 26-week treatment period, followed by a 5-week safety follow-up period.

Treatment Period
Participant flow — Treatment Period
Milestone500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Started365365
Received at least 1 dose of study drug365365
Completed348344
Not completed1721
Withdrew: Adverse event30
Withdrew: Assigned treatment by mistake43
Withdrew: Death01
Withdrew: Lost to follow-up21
Withdrew: Non-compliance with study drug13
Withdrew: Physician decision20
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject512
Follow-Up Period
Participant flow — Follow-Up Period
Milestone500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Started357354
Completed352349
Not completed55
Withdrew: Adverse event10
Withdrew: Death10
Withdrew: Lost to follow-up31
Withdrew: Withdrawal by subject04

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority]

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority]
Percentage of HbA1c500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority]-1.01 ± 0.0463-1.00 ± 0.0463
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · Ls mean difference: -0.012 · 95% CI -0.140 to 0.116
SecondaryChange From Baseline in HbA1c [Superiority]

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Percentage of HbA1c
Change From Baseline in HbA1c [Superiority]
Percentage of HbA1c500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Change From Baseline in HbA1c [Superiority]-1.01 ± 0.0463-1.00 ± 0.0463
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · ANCOVA · p = 0.855 · Ls mean difference: -0.012 · 95% CI -0.140 to 0.116
SecondaryPercentage of Participants Achieving HbA1c <7% Without Nocturnal Hypoglycemia

Percentage of participants achieving HbA1c \<7% without nocturnal hypoglycemia \[\<54 milligram/deciliter (mg/dL) 3.0 millimole/Liter (mmol/L)\] or severe during treatment phase up to week 26. Nocturnal hypoglycemia is a hypoglycemia event, including severe hypoglycemia, that occurs at night and presumably during sleep between midnight and 6:00 am.

Time frame:
Week 26
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving HbA1c <7% Without Nocturnal Hypoglycemia
Percentage of participants500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Percentage of Participants Achieving HbA1c <7% Without Nocturnal Hypoglycemia38.635.9
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · Chi-squared · p = 0.504 · Odds ratio (or): 1.11 · 95% CI 0.81 to 1.52
SecondaryNocturnal Hypoglycemia Event Rate

The event rate of participant-reported clinically significant nocturnal hypoglycemia, (where glucose \<54 mg/dL (3.0 mmol/L) or severe and occurs at night and presumably during sleep between midnight and 6:00 AM), measured during treatment phase up to week 26. Group mean is reported here.

Time frame:
Baseline Up To Week 26
Reported as:
Mean · Events per year
Nocturnal Hypoglycemia Event Rate
Events per year500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Nocturnal Hypoglycemia Event Rate0.67 ± 0.1121.00 ± 0.151
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · Negative binomial model · p = 0.058 · Relative rate: 0.67 · 95% CI 0.44 to 1.01Relative rate is the ratio of the group means (Insulin Efsitora vs Insulin Glargine).
SecondaryChange From Baseline in Fasting Glucose

Change from baseline in fasting glucose measured by self-monitoring blood glucose (SMBG).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · milligrams per deciliter (mg/dL)
Change From Baseline in Fasting Glucose
milligrams per deciliter (mg/dL)500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Change From Baseline in Fasting Glucose-30.87 ± 1.876-26.58 ± 1.871
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · ANCOVA · p = 0.104 · Ls mean difference: -4.29 · 95% CI -9.461 to 0.886
SecondaryPercentage of Time in Glucose Range

Percentage of Time in glucose range between 70 and 180 mg/dL (3.9 and 10.0 mmol/L), inclusive measured during the continuous glucose monitoring (CGM) session.

Time frame:
Week 22 to Week 26
Reported as:
Least squares mean · Percentage of time
Percentage of Time in Glucose Range
Percentage of time500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Percentage of Time in Glucose Range58.39 ± 0.99357.05 ± 0.990
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · ANCOVA · p = 0.337 · Ls mean difference: 1.35 · 95% CI -1.404 to 4.101
SecondaryPercentage of Time in Hypoglycemia Range

Percentage of Time in hypoglycemia range with glucose \<54 mg/dL (3.0 mmol/L), measured by CGM.

Time frame:
Week 22 to Week 26
Reported as:
Least squares mean · Percentage of time
Percentage of Time in Hypoglycemia Range
Percentage of time500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Percentage of Time in Hypoglycemia Range6.84 ± 0.7005.25 ± 0.680
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · ANCOVA · p = 0.104 · Ls mean difference: 1.59 · 95% CI -0.327 to 3.508
SecondaryPercentage of Time in Hyperglycemia Range

Percentage of Time in hyperglycemia range with glucose \>180 mg/dL (10.0 mmol/L), measured by CGM.

Time frame:
Week 22 to Week 26
Reported as:
Least squares mean · Percentage of time
Percentage of Time in Hyperglycemia Range
Percentage of time500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Percentage of Time in Hyperglycemia Range40.10 ± 1.02441.60 ± 1.024
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · ANCOVA · p = 0.304 · Ls mean difference: -1.50 · 95% CI -4.358 to 1.360
SecondaryGlucose Variability Between Weeks 22 to 26

Glucose variability measured as coefficient of variation for glucose within day for 24-hour period between Week 22 and 26 was reported.

Time frame:
Week 22 to Week 26
Reported as:
Least squares mean · Coefficient of Variation
Glucose Variability Between Weeks 22 to 26
Coefficient of Variation500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Glucose Variability Between Weeks 22 to 2628.51 ± 0.25928.28 ± 0.254
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · Mixed Models Analysis · p = 0.523 · Ls mean difference: 0.23 · 95% CI -0.48 to 0.95
SecondaryBasal Insulin Dose at Week 26

Average weekly basal Insulin Dose at Week 26 was reported.

Time frame:
Week 26
Reported as:
Least squares mean · Units per week of basal insulin
Basal Insulin Dose at Week 26
Units per week of basal insulin500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Basal Insulin Dose at Week 26391.59 ± 7.482426.62 ± 7.323
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -35.04 · 95% CI -55.57 to -14.50
SecondaryBolus Insulin Dose at Week 26

Average daily bolus Insulin Dose at Week 26 was reported.

Time frame:
Week 26
Reported as:
Least squares mean · Units per day of bolus insulin
Bolus Insulin Dose at Week 26
Units per day of bolus insulin500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Bolus Insulin Dose at Week 2627.01 ± 1.18234.56 ± 1.156
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -7.55 · 95% CI -10.79 to -4.30
SecondaryTotal Insulin Dose at Week 26

Average total weekly insulin dose at Week 26 was reported.

Time frame:
Week 26
Reported as:
Least squares mean · Units per week of insulin
Total Insulin Dose at Week 26
Units per week of insulin500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Total Insulin Dose at Week 26592.92 ± 12.560666.43 ± 12.144
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: -73.50 · 95% CI -107.81 to -39.20
SecondaryBasal Insulin Dose to Total Insulin Dose Ratio at Week 26

Basal insulin dose to total insulin dose ratio at Week 26 was reported.

Time frame:
Week 26
Reported as:
Least squares mean · Ratio
Basal Insulin Dose to Total Insulin Dose Ratio at Week 26
Ratio500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Basal Insulin Dose to Total Insulin Dose Ratio at Week 2670.09 ± 0.74966.55 ± 0.722
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · Mixed Models Analysis · p = <0.001 · Ls mean difference: 3.53 · 95% CI 1.49 to 5.58
SecondaryHypoglycemia Event Rate

Hypoglycemia event rate was reported. Hypoglycemia with glucose \<54 mg/dL (Level 2) or Severe Hypoglycemia (Level 3) was reported. A severe hypoglycemic event is characterized by altered mental or physical status requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions for the treatment of hypoglycemia. Group mean was reported here.

Time frame:
Baseline up to Week 26
Reported as:
Mean · Events per year
Hypoglycemia Event Rate
Events per year500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Hypoglycemia Event Rate6.58 ± 0.7095.94 ± 0.618
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · Negative binomial model · p = 0.442 · Mean difference (net): 1.11 · 95% CI 0.85 to 1.44
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight was reported.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · kilograms (kg)
Change From Baseline in Body Weight
kilograms (kg)500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Change From Baseline in Body Weight2.67 ± 0.1652.53 ± 0.165
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · Mixed Models Analysis · p = 0.543 · Ls mean difference: 0.14 · 95% CI -0.32 to 0.60
SecondaryTreatment Experience for Diabetes Injection Device at Week 26 - Experience Questionnaire (DID-EQ)

The DID-EQ is a self-administered, 10-item questionnaire designed to assess participants' perceptions of diabetes injection delivery systems for diabetes. The Device Characteristic Subscale is comprised of items 1 to 7 which focus on specific characteristics of injection devices. Each item is rated on a four-point Likert scale. Scores are transformed and range from 0 to 100. Higher scores indicate more positive perceptions of injection device characteristics

Time frame:
Week 26
Reported as:
Least squares mean · Score on a scale
Treatment Experience for Diabetes Injection Device at Week 26 - Experience Questionnaire (DID-EQ)
Score on a scale500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
Treatment Experience for Diabetes Injection Device at Week 26 - Experience Questionnaire (DID-EQ)88.1 ± 0.7786.3 ± 0.75
Statistical analysis
  • 500 U/mL - Insulin Efsitora vs 100 U/mL - Insulin Glargine · ANCOVA · p = 0.099 · Ls mean difference: 1.8 · 95% CI -0.3 to 4.0

Adverse events

Collected over Baseline Through Safety Follow-Up (Up To 31 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
500 U/mL - Insulin Efsitora1/365 (0.3%)25/365 (6.8%)35/365 (9.6%)
100 U/mL - Insulin Glargine1/365 (0.3%)24/365 (6.6%)40/365 (11%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
Event500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
HypoglycaemiaMetabolism and nutrition disorders5/3655/365
PneumoniaInfections and infestations3/3651/365
Cardiac arrestCardiac disorders2/3650/365
Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1930/176
Acute myocardial infarctionCardiac disorders1/3651/365
Angina pectorisCardiac disorders1/3650/365
Arteriosclerosis coronary arteryCardiac disorders1/3650/365
Atrioventricular blockCardiac disorders1/3650/365
Cardiac failure congestiveCardiac disorders1/3650/365
Left ventricular failureCardiac disorders0/3651/365
Most frequent other events
Most frequent other events
Event500 U/mL - Insulin Efsitora100 U/mL - Insulin Glargine
NasopharyngitisInfections and infestations23/36521/365
InfluenzaInfections and infestations14/36519/365

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)500 U/mL - Insulin Efsitora100 U/mL - Insulin GlargineTotal
Mean58.3 ± 10.559.4 ± 10.558.9 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)500 U/mL - Insulin Efsitora100 U/mL - Insulin GlargineTotal
Female193176369
Male172189361
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)500 U/mL - Insulin Efsitora100 U/mL - Insulin GlargineTotal
Hispanic or Latino201203404
Not Hispanic or Latino163161324
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)500 U/mL - Insulin Efsitora100 U/mL - Insulin GlargineTotal
American Indian or Alaska Native464591
Asian5451105
Native Hawaiian or Other Pacific Islander000
Black or African American201131
White245258503
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)500 U/mL - Insulin Efsitora100 U/mL - Insulin GlargineTotal
Argentina8383166
Germany272451
India5050100
Italy111526
Mexico8584169
Spain353570
United States7474148
HemoglobinA1c (HbA1c)
HemoglobinA1c (HbA1c)(Percentage of HbA1c)500 U/mL - Insulin Efsitora100 U/mL - Insulin GlargineTotal
Mean8.17 ± 0.838.18 ± 0.798.18 ± 0.81
08

Study locations

81 sites
  • CMR of Greater New Haven, LLC
    Hamden, Connecticut 06517, United States
  • Tampa Bay Medical Research
    Clearwater, Florida 33761, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014, United States
  • Encore Medical Research - Weston
    Weston, Florida 33331, United States
  • Elite Clinical Trials
    Blackfoot, Idaho 83221, United States
  • Rocky Mountain Clinical Research
    Idaho Falls, Idaho 83404, United States
  • MedStar Good Samaritan Hospital
    Baltimore, Maryland 21239, United States
  • NECCR PrimaCare Research
    Fall River, Massachusetts 02721, United States
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
    Troy, Michigan 48098, United States
  • Palm Research Center Tenaya
    Las Vegas, Nevada 89128, United States
  • Palm Research Center Sunset
    Las Vegas, Nevada 89148, United States
  • Research Foundation of SUNY - University of Buffalo
    Buffalo, New York 14221, United States
  • Remington Davis Clinical Research
    Columbus, Ohio 43215, United States
  • Aventiv Research
    Dublin, Ohio 43016, United States
  • Heritage Valley Multispecialty Group, Inc
    Beaver, Pennsylvania 15009, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78731, United States
  • Texas Diabetes & Endocrinology, P.A.
    Austin, Texas 78749, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77043, United States
  • Research Institute of Dallas
    Plano, Texas 75093, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Chrysalis Clinical Research
    Saint George, Utah 84790, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • CEDIC
    Caba, Buenos Aires C1060ABN, Argentina
  • Centro de Investigaciones Metabólicas (CINME)
    Ciudad Autónoma de Buenos Aire, Buenos Aires 1056, Argentina
  • Go Centro Medico San Nicolás
    San Nicolas, Buenos Aires 2900, Argentina
  • Consultorio de Investigación Clínica EMO SRL
    Ciudad Autonoma de Buenos Aire, Buenos Air C1405BUB, Argentina
  • Mautalen Salud e Investigación
    Buenos Aires, Ciudad Autónoma De Buenos Aires C1128AAF, Argentina
  • CIPREC
    Caba, Ciudad Autónoma De Buenos Aires C1061AAS, Argentina
  • Instituto Centenario
    Caba, Ciudad Autónoma De Buenos Aire 1204, Argentina
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada
    Ciudad Autonoma de Buenos Aire, Ciudad Autónoma De Buenos Aire C1425AGC, Argentina
  • Instituto Médico Río Cuarto
    Río Cuarto, Córdoba 5800, Argentina
  • Centro de Salud e Investigaciones Médicas
    Santa Rosa, La Pampa 6300, Argentina
  • Instituto de Investigaciones Clinicas Rosario-Sanatorio Delta
    Rosario, Santa Fe 2000, Argentina
  • Instituto Médico Catamarca IMEC
    Rosario, Santa Fe 2000, Argentina
  • Centro de Investigaciones Médicas Tucuman
    San Miguel De Tucumán, Tucumán T4000AXL, Argentina
  • CENUDIAB
    Ciudad Autónoma de Buenos Aires, C1440AAD, Argentina
  • Instituto de Investigaciones Clínicas Córdoba
    Córdoba, 5000, Argentina
  • Centro de Investigaciones Clinicas del Litoral
    Santa Fe, 3000, Argentina
  • ClinPhenomics GmbH & Co KG
    Frankfurt, Hessen 60596, Germany
  • InnoDiab Forschung Gmbh
    Essen, Nordrhein-Westfalen 45136, Germany
  • Institut für Diabetesforschung GmbH Münster
    Münster, Nordrhein-Westfalen 48145, Germany
  • Schwerpunktpraxis für Diabetes und Ernährungsmedizin Dr. med. Winfried Keuthage
    Münster, Nordrhein-Westfalen 48153, Germany
  • RED-Institut GmbH
    Oldenburg, Schleswig-Holstein 23758, Germany
  • Diabetespraxis Mergentheim
    Bad Mergentheim, 97980, Germany
  • Diabeteszentrum Hamburg West
    Hamburg, 22607, Germany
  • Life Care Hospital and Research Centre
    Bangalore, Karnataka 560092, India
  • Topiwala National Medical College & B. Y. L. Nair Charitable Hospital
    Mumbai, Maharashtra 400008, India
  • BSES MG Hospital
    Mumbai, Maharashtra 400058, India
  • Madras Diabetes Research Foundation
    Chennai, Tamil Nadu 600086, India
  • Osmania General Hospital
    Hyderabad, Telangana 500012, India
  • Post Graduate Institute of Medical Education & Research (PGIMER)
    Chandigarh, 160012, India
  • Osepdale Civile Fr 5
    Ceccano, Frosinone 03023, Italy
  • "Fatebenefratelli Isola Tiberina - Gemelli Isola"
    Roma, Lazio 00186, Italy
  • Ospedale san Giovanni di Dio-Diabetologia
    Olbia, Sardegna 07026, Italy
  • INRCA Ancona
    Ancona, 60125, Italy
  • IRCCS - AOU di Bologna
    Bologna, 40138, Italy
  • Azienda Ospedaliera Spedali Civili di Brescia
    Brescia, 25123, Italy
  • Azienda Ospedaliera Mater Domini
    Catanzaro, 88100, Italy
  • Azienda di Rilievo Nazionale e Alta Specializzazione Civico Di Cristina Benfratelli
    Palermo, 90127, Italy
  • Private Practice - Dr. Arechavaleta Granell Maria del Rosario
    Guadalajara, Jalisco 44670, Mexico
  • Unidad de Investigación Clínica y Atención Médica HEPA
    Guadalajara, Jalisco 44670, Mexico
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
    Monterrey, Nuevo León 66460, Mexico
  • Unidad Médica para la Salud Integral
    San Nicolás de los Garza, Nuevo León 66465, Mexico
  • Centro de Estudios de Investigacion Metabolicos y Cardiovasculares, S.C.
    Ciudad Madero, Tamaulipas 89440, Mexico
  • Investigacion En Salud Y Metabolismo Sc
    Chihuahua, 31217, Mexico
  • Centro de Endocrinologia Alcantara Gonzalez
    Bayamon, 00959, Puerto Rico
  • Manati Center for Clinical Research
    Manati, 00674, Puerto Rico
  • CHUAC-Complejo Hospitalario Universitario A Coruña
    A Coruña, A Coruña [La Coruña] 15006, Spain
  • Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval
    Ferrol, A Coruña [La Coruña] 15405, Spain
  • Hospital Universitario Virgen de la Victoria
    Malaga, Andalucía 29010, Spain
  • Hospital Universitari Son Espases
    Palma, Balears [Baleares] 07120, Spain
  • Hospital Clínico Universitario de Valladolid
    Valladolid, Castilla Y León 47010, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Catalunya [Cataluña] 08041, Spain
  • Hospital Universitario Quironsalud Madrid
    Pozuelo de Alarcón, Madrid 28223, Spain
  • Vithas Hospital Sevilla
    Seville, Sevilla 41950, Spain
  • Hospital Universitario de La Ribera
    Alzira, Valenciana, Comunitat 46600, Spain
  • Hospital General Universitario de Valencia
    Valencia, Valenciana, Comunitat 46014, Spain
  • Hospital Universitario San Cecilio
    Granada, 18016, Spain
  • Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
    Sevilla, 41003, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Feb 2024, 18 months.

Results were first posted in Apr 2025, 1 year 2 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2022
First posted
Jul 18, 2022
StartActual
Aug 11, 2022
Primary completionActual
Feb 27, 2024
CompletionActual
Feb 27, 2024
Results first posted
Apr 27, 2025
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05462756
Responsible party
Sponsor
First posted
Jul 18, 2022
Start date
Aug 11, 2022
Primary completion
Feb 27, 2024
Completion
Feb 27, 2024
Results posted
Apr 27, 2025
Last update
Apr 27, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) Mon- Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin efsitora alfa · Insulin Glargine

Start the discussion